Impact BioMedical, Inc. (IBO)

Impact BioMedical, Inc. is a company focused on research and development of health and wellness products and drug candidates. It has been majority-owned by DSS, Inc., a diversified holding company.

Its programs have included work on anti-inflammatory and pain-related compounds, antiviral research, and consumer-oriented products, with the company seeking to develop or license its technologies to partners. Its common stock trades on NYSE American under the ticker IBO.